Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:ELUT NASDAQ:MGX NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$1.82-3.2%$2.44$1.58▼$9.98$44.98M0.52126,888 shs82,411 shsELUTElutia$0.99-4.8%$1.09$0.50▼$2.64$44.50M0.8129,072 shs145,748 shsMGXMetagenomi$1.33$1.38$1.24▼$3.95$50.07M0.64192,931 shs151,759 shsPHIOPhio Pharmaceuticals$1.11-0.9%$1.18$0.81▼$4.19$13.01M0.82133,340 shs54,443 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-3.19%-13.74%-39.33%-43.13%-81.33%ELUTElutia-4.80%-12.38%-1.97%-10.80%-48.96%MGXMetagenomi0.00%-1.48%-4.32%-17.39%-24.86%PHIOPhio Pharmaceuticals-0.89%+0.91%-2.63%-5.13%-46.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$1.82-3.2%$2.44$1.58▼$9.98$44.98M0.52126,888 shs82,411 shsELUTElutia$0.99-4.8%$1.09$0.50▼$2.64$44.50M0.8129,072 shs145,748 shsMGXMetagenomi$1.33$1.38$1.24▼$3.95$50.07M0.64192,931 shs151,759 shsPHIOPhio Pharmaceuticals$1.11-0.9%$1.18$0.81▼$4.19$13.01M0.82133,340 shs54,443 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-3.19%-13.74%-39.33%-43.13%-81.33%ELUTElutia-4.80%-12.38%-1.97%-10.80%-48.96%MGXMetagenomi0.00%-1.48%-4.32%-17.39%-24.86%PHIOPhio Pharmaceuticals-0.89%+0.91%-2.63%-5.13%-46.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.50861.54% UpsideELUTElutia 2.50Moderate Buy$6.00506.00% UpsideMGXMetagenomi 2.80Moderate Buy$9.00576.69% UpsidePHIOPhio Pharmaceuticals 2.00Hold$14.001,161.26% UpsideCurrent Analyst Ratings BreakdownLatest PHIO, ELUT, MGX, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/12/2026MGXMetagenomi Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.005/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.004/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/27/2026ACTUActuate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.34 per shareN/AELUTElutia$12.29M3.45N/AN/A$0.65 per share1.52MGXMetagenomi$25.21M1.99N/AN/A$4.22 per share0.32PHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$0.97N/AN/AN/AN/A-430.93%-180.86%N/AELUTElutia$53.38M$0.861.15N/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)MGXMetagenomi-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)Latest PHIO, ELUT, MGX, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ACTUActuate Therapeutics-$0.23-$0.24-$0.01-$0.24N/AN/A5/14/2026Q1 2026ELUTElutia-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million5/11/2026Q1 2026MGXMetagenomi-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/A3/26/2026Q4 2025ACTUActuate Therapeutics-$0.24-$0.18+$0.06-$0.18N/AN/A3/11/2026Q4 2025ELUTElutia-$0.14-$0.14N/A$1.48$3.30 million$3.30 million3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 million3/5/2026Q4 2025PHIOPhio Pharmaceuticals-$0.34-$0.15+$0.19-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.801.80ELUTElutiaN/A2.051.94MGXMetagenomiN/A6.436.43PHIOPhio PharmaceuticalsN/A18.3218.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AELUTElutia74.03%MGXMetagenomiN/APHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%ELUTElutia27.60%MGXMetagenomi12.50%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.93 million10.05 millionN/AELUTElutia18042.78 million30.98 millionNot OptionableMGXMetagenomi23637.65 million32.94 millionN/APHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionablePHIO, ELUT, MGX, and ACTU HeadlinesRecent News About These CompaniesPhio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesMay 27, 2026 | tennessean.comTPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 8, 2026 | finanznachrichten.dePhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 7, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...April 14, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026April 13, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026April 9, 2026 | finance.yahoo.comPyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology CandidateApril 8, 2026 | jsonline.comJPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 31, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 30, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...March 23, 2026 | finance.yahoo.comPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline AdvancementMarch 23, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | newsfilecorp.comNB2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured ConferenceMarch 11, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | finanznachrichten.dePhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHIO, ELUT, MGX, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$1.82 -0.06 (-3.19%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.37%) As of 06/3/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Elutia NASDAQ:ELUT$0.99 -0.05 (-4.80%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.00%) As of 06/3/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Metagenomi NASDAQ:MGX$1.33 0.00 (0.00%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.38%) As of 06/3/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Phio Pharmaceuticals NASDAQ:PHIO$1.11 -0.01 (-0.89%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$1.12 +0.00 (+0.45%) As of 06/3/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
